|Description||BW 245C, a prostaglandin analogue, is a selective prostanoid DP-receptor (DP1)agonist used to treat stroke where the Ki for the inhibition of [3H]-PGD2 binding to isolated human platelet membranes is 0.9 nM and has a reported IC50 of 2.5 nM for the inhibition of ADP-induced human platelet aggregation.|
|Brife Description||A prostanoid DP-receptor (DP1) agonist|
|Synonyms||7-[(4S)-3-[(3R)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxoimidazolidin-4-yl]heptanoic acid; 245C77; 5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)hydantoin; BW 245C; BW 245C, (R*,S*)-(+-); BW-245C|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
A EP1 antagonist (pKi= 7.54) (pIC50= 8.5)
CP-533536, also called as Evatanepag, a 3-pyridyl sulfonamide compound, demonstrated excellent in vitro potency against prostaglandin E2 (PGE2) (induces local b...
Laropiprant is a potent, selective DP1 receptor antagonist (Ki=0.57 nM) used in combination with niacin to reduce blood cholesterol (LDL and VLDL).
Ethamsylate is a haemostatic drug, which inhibits biosynthesis and action of prostaglandins, and increases capillary endothelial resistance as and platelet adhe...
Prostaglandin-E1 is used as a drug in the treatment of erectile dysfunction and has vasodilatory properties. It can be used as a vasodilator agent increasing pe...
FR-181157 is an orally active prostacyclin mimetic that shows high potency and agonist efficacy at the IP receptor.
(+)-Cloprostenol sodium salt
(+)-Cloprostenol sodium salt is the d-enantiomer of Cloprostenol, which is an aryl-oxymethyl analog of prostaglandin F2α. It has luteolytic effects and is used ...
CP 544326, also known as taprenepag, is a potent and selective EP(2) receptor agonist. Its EC50 value is 2.8 nM. It is the active acid metabolite of the prodrug...
Iloprost is a drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are cons...
ONO-AE3-208 is an EP4 antagonist (Ki values are 1.3, 30, 790 and 2400 nM for EP4, EP3, FP and TP receptors respectively), which less potently affects EP3, FP, a...
GW 627368X is a potent and selective competitive antagonist of the EP4 receptor with additional human TP receptor affinity (Ki values of 100 nM and 158 nM, resp...
PF-04418948 is a potent and selective prostaglandin EP₂ receptor antagonist with IC50 of 16 nM. Phase 1. PF-04418948 antagonizes the effects of butaprost and PG...
PF-04217329 is a potent and selective EP2 receptor agonist on intraocular pressure in preclinical models of glaucoma. It is a prodrug of CP-544326. It is well t...
Ifetroban is a selective Prostaglandin receptor and Thromboxane A2 receptor antagonist under the development of Bristol-Myers Squibb. Phase II clinical trials f...
Terutroban is a potent, orally active antagonist of the thromboxane/prostaglandin A2(TP) receptor (IC50 = 16.4 nM). In guinea pigs it also inhibits U 46619 indu...
E7046 is an orally bioavailable and specific type 4 prostaglandin E2 (PGE2) receptor EP antagonist (IC50= 13.5 nM) (Ki= 23.14 nM), with anti-tumor activities.
This active molecular is a potent Prostaglandin D2 receptor antagonists and has been in phase I clinical trials for both COPD (chronic obstructive pulmonary dis...
CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist. It inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5. It ...
Grapiprant, also known as CJ-023,423, RQ-00000007 and AAT-007, is a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic prop...
BW 245C, a prostaglandin analogue, is a selective prostanoid DP-receptor (DP1)agonist used to treat stroke where the Ki for the inhibition of [3H]-PGD2 binding ...